Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

September 30, 2013

Conditions
Tourette's DisorderTic Disorder
Interventions
DRUG

Aripiprazole

Once-daily, tablet

DRUG

Placebo

Trial Locations (75)

Unknown

Dothan

Goodyear

Tucson

Corona

Sacramento

San Diego

Santa Ana

Wildomar

Norwich

Bradenton

Gainsville

Leesburg

Maitland

Miami

Orange City

Orlando

St. Petersburg

Tampa

Atlanta

Columbus

Savannah

Naperville

Indianapolis

Overland Park

Wichita

Louisville

Waldorf

Bloomfield Hills

Mount Arlington

Summit

Albuquerque

Manhasset

New York

Rochester

Staten Island

Durham

Cleveland

Middleburg Heights

Oklahoma City

Eugene

Philadelphia

Mt. Pleasant

Nashville

Austin

Dallas

Houston

San Antonio

Orem

Salt Lake City

Charlottesville

Henrico

Norfolk

Bellevue

Bothell

Middleton

Kentville

Parry Sound

Toronto

Whitby

Dresden

Freiburg im Breisgau

Mannheim

Würzburg

Budapest

Szeged

Catania

Milan

Roma

Mexico City

Durango

Leon

Bucharest

Iași

Madrid

Gothenburg

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT01727700 - Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder | Biotech Hunter | Biotech Hunter